BRAHMS GmbH

Patent Applications and Registrations

Patent applications and USPTO patent grants for BRAHMS GmbH.The latest application filed is for "diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin ii".

Company Profile

3.7.14

BRAHMS GmbH - Henningsdorf N/A DE
BRAHMS GmbH - Hennigsdorf N/A DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Diagnosis and risk stratification of infections and chronic diseases of the respiratory tract and lungs by means of provasopressin, particularly copeptin or neurophysin II Grant 10,718,783 - Bergmann , et al.	2020-07-21
In vitro method for early or differential diagnosis or prognosis of myocardial infarction in a patient Grant 10,254,289 - Bergmann , et al.	2019-04-09
Diagnosis and risk stratification by determining the marker CT-proADM Grant 9,726,675 - Bergmann , et al. August 8, 2	2017-08-08
Diagnosis And Risk Stratification Of Infections And Chronic Diseases Of The Respiratory Tract And Lungs By Means Of Provasopressin, Particularly Copeptin Or Neurophysin Ii App 20170059583 - BERGMANN; Andreas ; et al.	2017-03-02
Diagnosis and Risk Assessment of Pancreatic Diabetes Using MR-proADM App 20160169912 - Bergmann; Andreas ; et al.	2016-06-16
DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1 App 20160161505 - Bergmann; Andreas ; et al.	2016-06-09
Risk Stratification for Acute Coronary Syndrome by Means of Fragments/Partial Peptides of Provasopressin, Especially Copeptin or Neurophysin II App 20160131660 - Bergmann; Andreas ; et al.	2016-05-12
Diagnosis of acute coronary syndrome, myocardial infarction, or angina pectoris by means of neurophysin II Grant 9,261,517 - Bergmann , et al. February 16, 2	2016-02-16
Methods Of Diagnosis And Risk Stratification Of Adverse Events In Post Myocardial Infarction Patients Using Pro-adrenomedullin App 20150192595 - NG; LEONG L. ; et al.	2015-07-09
Diagnosis And Risk Stratification By Means Of The Novel Marker Ct-proadm App 20150011017 - BERGMANN; ANDREAS ; et al.	2015-01-08
Diagnosis and risk stratification by determining the marker CT-proADM Grant 8,853,355 - Bergmann , et al. October 7, 2	2014-10-07
Risk Stratification For Acute Coronary Syndrome By Means Of Fragments/partial Peptides Of Provasopressin, Especially Copeptin Or Neurophysin Ii App 20130344513 - Bergmann; Andreas ; et al.	2013-12-26
Diagnosis And Risk Stratification By Means Of The Novel Marker Ct-proadm App 20130266961 - Bergmann; Andreas ; et al.	2013-10-10
Diagnosis and risk stratification by determining the marker CT-proADM Grant 8,436,135 - Bergmann , et al. May 7, 2	2013-05-07
Diagnosis And Risk Stratification Of Infections And Chronic Diseases Of The Respiratory Tract And Lungs By Means Of Provasopressin, Particularly Copeptin Or Neurophysin Ii App 20120270245 - Bergmann; Andreas ; et al.	2012-10-25

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.